Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Gains from Sales and Divestitures (2024 - 2025)

Prelude Therapeutics' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $37500.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 11.76% year-over-year to $37500.0; the TTM value through Dec 2025 reached $37500.0, down 11.76%, while the annual FY2025 figure was $37500.0, 11.76% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $37500.0 at Prelude Therapeutics, up from $28125.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $42500.0 in Q4 2024 and bottomed at $9375.0 in Q1 2025.